BioXcel Therapeutics
BTAI
BTAI
19 hedge funds and large institutions have $25M invested in BioXcel Therapeutics in 2018 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
27% less capital invested
Capital invested by funds: $34.2M → $25M (-$9.21M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Holders
19
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$142K | |
| 2 | +$126K | |
| 3 | +$102K | |
| 4 |
Morgan Stanley
New York
|
+$31.3K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$24K |
Top Sellers
| 1 | -$2.67M | |
| 2 | -$421K | |
| 3 | -$358K | |
| 4 |
PAM
Prudence Asset Management
Hong Kong
|
-$272K |
| 5 |
MWNA
Marshall Wace North America
New York
|
-$174K |